Graphite Bio co-founder de­buts Treg cell ther­a­py start­up with $75M, aims to ‘trick’ im­mune sys­tem in­to re­set­ting

Tr1x launched from stealth Wednes­day with $75 mil­lion to tack­le graft-ver­sus-host dis­ease in ad­di­tion to in­flam­ma­to­ry and au­toim­mune con­di­tions.

The biotech was cre­at­ed by Maria Grazia Ron­car­o­lo, the Stan­ford Med­i­cine sci­en­tist who co-found­ed Graphite Bio and Ka­mau Ther­a­peu­tics. Bill Lis, who pre­vi­ous­ly led Jasper Ther­a­peu­tics and Por­to­la Phar­ma­ceu­ti­cals, is Tr1x’s CEO.

Ron­car­o­lo’s team was the first to dis­cov­er a type of im­mune cell called type 1 reg­u­la­to­ry T cells — or Tr1 cells — the name­sake of the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER